Introduction
Leptin receptor (LEPR) deficiency is a rare cause of obesıty. LEPR deficiency causes the clinical effects to begin in the first few months of life (1) . Though most of the affected patients lie in the normal range of birth weight, yet, they start gaining weight quickly due to the constant hunger. Right from the early childhood, patients have hyperphagia and develop their own abnormal eating behaviors that may include fighting for the food or even eating secretly. Nevertheless, the most important clinical outcome of these patients is the effect on sexual development. LEPR deficient patients have hypogonadotropic hypogonadism which may result in infertility (1) (2) (3) . LEPR deficiency is caused by mutations in LEPR gene that encodes the leptin receptor protein on the surface of many cells but is expressed mostly in the hypothalamus (2, 4) . It is also one of the rare diseases with an autosomal recessive inheritance pattern, affecting the morbid obesity group (2) . Mutations in LEPR gene causes a deficiency in the leptin receptors or an in-effective receptor complex. Consequently, this loss of function prevents the receptor from responding to leptin released from the fat cells. This triggers the activation of a series of signaling pathways, leading to excessive hunger, weight gain and decreased sexual development (4-9). However, the mechanism of these effects is not yet completely understood. This inherited obesity resulting from LEPR deficiency is difficult to diagnose, due to considerable clinical overlap and since most patients typically do not show signs and symptoms of the condition (10, 11) . Hence, molecular tests are required to obtain a conclusive diagnosis as well as to have the benefits of diagnosis including the pre-symptomatic diagnosis and screening, prevention, treatment, prognosis, and research. Genetic counselling, together with clinical evaluation, plays a critical role in the appropriate use of molecular tests. In this study, the clinical utility of molecular testing and the importance of polymorphisms that are mostly underestimated by many laboratories and clinicians have been outlined by the authors using the experiences they have gained.
Material and Methods
This study was carried out on the biological samples collected from The Cellular and Tissue Biobank of Cukurova University, Balcali Hospital and Clinics that focuses on rare diseases. A total of, sixteen pediatric patients (mean age of 21±1 months) with LEPR deficiency were referred to AGENTEM (Adana Genetic Diseases Diagnosis and Treatment Center), Cukurova University for molecular studies, and genetic counseling. In order to identify the molecular basis, the genetic analysis including leptin receptor deficiency related LEPR gene was employed as a molecular diagnostics tool by using nextgeneration sequencing platform (MiSeq System, Illumina). The coverage of the test included all exons for each gene, at least 50 nucleotides upstream and downstream of each exon and 1 kb of both the 5' promoter regions and the 3' UTRs. Sequencing was performed on the leukocyte DNA collected from 16 patients with LEPR deficiency. In-silico analysis for the novel mutations was carried out using SIFT, PolyPhen2 and Mutation Taster. All changes considered to have potential clinical relevance were confirmed by paternal testing to identify the carrier status. ClinCalc (http://clincalc.com) was used to determine the post-hoc power of the study and to apply the Bonferroni correction. All the statistical analyses were performed using the GraphPad Prism software (GraphPad Software, Inc. USA), while the statistical significance was defined at p≤0.05. HardyWeinberg equilibrium analysis was performed for each polymorphism identified. A modified version of the human genome (www.varsome.com) was used as the major allele population-specific reference. Confidence interval (CI) as 95% was used to estimate the precision of the odds ratio. The chi-square test was also used to test the frequencies of the alleles and genotypes. All the procedures performed in this study were in accordance with the ethical standards of the institutional ethical and national research committee and the Helsinki declaration. Informed consent of the patients and their families were conducted to keep all the information confidential was taken before the study began.
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Results and Discussion
All genetic variants detected in the patients are listed in Table 1 within the column homozygosity status. The causative mutations were identified in three out of the sixteen patients (Patient 1, 2 and 3; sum up 18.75%) affected with LEPR deficiency and there was a novel homozygous p.P639L (c.1916C>T) mutation, in all these three patients, as shown in Figure 1 . Neither of these patients had any consanguinity nor did they belong to the same city, but all had a middle-eastern origin. The insilico analysis revealed that this variant was pathogenic and the mutation was a diseasecausing one. Thus, paternal studies were performed and it was found that the mothers and fathers of all these three patients were first degree cousins and were heterozygous for the p.P639L (c.1916C>T) mutation in LEPR gene which confirms the results. This might have occurred because of the probability of carrying this mutation at a high frequency that can be speculated as a founder mutation in LEPR gene. However, further population studies must be carried out to support this conclusion.
The other significant data from this study included the frequency of polymorphisms that are mostly underestimated and usually left unreported in the genetic test reports. Ten out of the sixteen patients (62.5%) had at least one or more polymorphisms, as given in Table 1 . Among all the polymorphisms detected (n=10) in patients with LEPR deficiency, p.Q223R (c.668A>G) was the most common. Six out of these ten patients (60%) also showed other polymorphisms along with p.Q223R (c.668A>G). Patients 4, 5 and 6 had two homozygote polymorphisms of p.K109R (c.326A>G) and p.Q223R (c.668A>G). The frequency of these alterations in heterozygous population is high, around 40% (3, 12). However, there are also studies indicating that homozygous p.K109R polymorphism is related to increased birth weight and body-mass index (2, 10, 13). The homozygous p.Q223R variant was found to be significantly associated with obesity in previous studies (14) . A study also suggests that when these two variants occur together, they are also associated with glucose intolerance (15, 16 It is therefore important to carry out MLPA (multiplex ligation-depending probe amplification) for the deletion and duplication analysis of LEPR gene. Unfortunately, no MLPA probe has been designed for in-vitro diagnosis.
However, the undiagnosed LEPR deficiency patients in whom, genetic testing was not helpful in identifying the disease, might have had yet uncharacterized mutations in other genes. For each of the 16 patients tested, at least one variant detected in 81.25% of the patients (n=13). In-silico analysis and family studies were performed to help define the pathogenicity of the novel changes. In addition to the polymorphisms, the causative novel mutation was identified in three out of sixteen patients. More interestingly, the identified alterations that are classified as polymorphisms, may have had an effect on the clinical findings, as per the literature review and data from the present study (16) . The data in this, therefore, proposes a greater effort in the molecular diagnosis of rare diseases with appropriate genetic reporting in favor of diagnosis and prevention, and not just the control of co-morbidities, with the aim of enhancing the prognosis and a closer follow-up for the patients in order to improve their quality of life. 
Conclusion
To summarize, the availability of molecular genetic testing has profound implications for the clinicians, patients and their families. The benefits of genetic testing can be utilized for the diagnoses including the presymptomatic diagnosis and screening, prevention, treatment, prognosis, and research. However, a challenge still exists in the field of genomics that when potential novel genes/mutations/polymorphisms or phenotypes are detected, large group studies, functional studies, and model systems are needed. At the last place, even if a disease is monogenetic as in case of LEPR deficiency, results will still outcome as non-diagnostic or only about susceptibility due to possible defects on other genes or the epigenetic factors such as DNA methylation and histone modification, or epistasis.
In this study, a novel mutation, which is a disease-causing mutation, was identified in three different patients. The compound homo/heterozygosity for the polymorphisms was also determined that has helped in a better understanding of its association with obesity, increased body mass index, insulin resistance, and the glucose intolerance. While allelic heterogeneity can result in varying phenotypic severity, phenotypically identical disorders can also have an entirely different genetic basis (genocopy). It is, therefore, critical to identify the mutation/polymorphismassociated risks by molecular analysis. It is also important not to underestimate the disease associated polymorphisms that has to be specified in genetic testing reports. Acknowledgement: We sincerely thank the patients and the families that have enrolled. We also recognize the contribution of our laboratory staff for their considerable efforts in providing comprehensive testing. This work was supported by the grants from the Cukurova University Scientific Research Projects Coordination Unit (TAY-2016-4020), Adana, Turkey. Source of Finance: During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.
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